Challenges to successful outcomes in AYAs with ALL and potential solutions

2.

Iacobucci

I

,

Mullighan

CG

.

Genetic basis of acute lymphoblastic leukemia

.

J Clin Oncol

.

2017

;

35

(

9

):

975

-

983

.

doi:10.1200/JCO.2016.70.7836

.

3.

Den Boer

ML

,

van Slegtenhorst

M

,

De Menezes

RX

, et al.

A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study

.

Lancet Oncol

.

2009

;

10

(

2

):

125

-

134

.

doi:10.1016/s1470-2045(08)70339-5

.

4.

Stock

W

,

Luger

SM

,

Advani

AS

, et al.

A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403

.

Blood

.

2019

;

133

(

14

):

1548

-

1559

.

doi:10.1182/blood-2018-10-881961

.

5.

Jain

N

,

Roberts

KG

,

Jabbour

E

, et al.

Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults

.

Blood

.

2017

;

129

(

5

):

572

-

581

.

doi:10.1182/blood-2016-07-726588

.

6.

Roberts

KG

,

Li

Y

,

Payne-Turner

D

, et al.

Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia

.

N Engl J Med

.

2014

;

371

(

11

):

1005

-

1015

.

doi:10.1056/NEJMoa1403088

.

7.

Herold

T

,

Schneider

S

,

Metzeler

KH

, et al.

Adults with Philadelphia chromosome-like acute lymphoblastic leukemia frequently have IGH-CRLF2 and JAK2 mutations, persistence of minimal residual disease and poor prognosis

.

Haematologica

.

2017

;

102

(

1

):

130

-

138

.

doi:10.3324/haematol.2015.136366

.

8.

Roberts

KG

,

Gu

Z

,

Payne-Turner

D

, et al.

High frequency and poor outcome of Philadelphia chromosome-like acute lymphoblastic leukemia in adults

.

J Clin Oncol

.

2017

;

35

(

4

):

394

-

401

.

doi:10.1200/JCO.2016.69.0073

.

9.

Chiaretti

S

,

Messina

M

,

Della Starza

I

, et al.

Philadelphia-like acute lymphoblastic leukemia is associated with minimal residual disease persistence and poor outcome. First report of the minimal residual disease-oriented GIMEMA LAL1913

.

Haematologica

.

2021

;

106

(

6

):

1559

-

1568

.

doi:10.3324/haematol.2020.247973

.

10.

Tasian

SK

,

Assad

A

,

Hunter

DS

,

Du

Y

,

Loh

ML.

A phase 2 dtudy of ruxolitinib with chemotherapy in children with Philadelphia chromosome-like acute lymphoblastic leukemia (INCB18424-269/AALL1521): dose-finding results from the part 1 safety phase

.

Blood

.

2018

;

132

(

suppl 1

):

555

.

doi:10.1182/blood-2018-99-110221

.

11.

Tasian

SK

,

Teachey

DT

,

Li

Y

, et al.

Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia

.

Blood

.

2017

;

129

(

2

):

177

-

187

.

doi:10.1182/blood-2016-05-707653

.

12.

Hurtz

C

,

Wertheim

GB

,

Loftus

JP

, et al.

Oncogene-independent BCR-like signaling adaptation confers drug resistance in Ph-like ALL

.

J Clin Invest

.

2020

;

130

(

7

):

3637

-

3653

.

doi:10.1172/JCI134424

.

13.

Tsuzuki

S

,

Yasuda

T

,

Goto

H

, et al.

BCL6 inhibition ameliorates resistance to ruxolitinib in CRLF2-rearranged acute lymphoblastic leukemia

.

Haematologica

.

2023

;

108

(

2

):

394

-

408

.

doi:10.3324/haematol.2022.280879

.

14.

Ding

YY

,

Loftus

JP

,

Mathier

B

, et al.

Transcriptional rewiring and therapeutic resistance in Philadelphia chromosome-like acute lymphoblastic leukemia

.

Blood

.

2022

;

140

(

suppl 1

):

354

-

355

.

doi:10.1182/blood-2022-169341

.

15.

Jabbour

E

,

Patel

K

,

Jain

N

, et al.

Impact of Philadelphia chromosome-like alterations on efficacy and safety of blinatumomab in adults with relapsed/refractory acute lymphoblastic leukemia: a post hoc analysis from the phase 3 TOWER study

.

Am J Hematol

.

2021

;

96

(

10

):

E379

-

E383

.

doi:10.1002/ajh.26281

.

16.

Leahy

AB

,

Devine

KJ

,

Li

Y

, et al.

Impact of high-risk cytogenetics on outcomes for children and young adults receiving CD19-directed CAR T-cell therapy

.

Blood

.

2022

;

139

(

14

):

2173

-

2185

.

doi:10.1182/blood.2021012727

.

17.

Meyer

C

,

Burmeister

T

,

Gröger

D

, et al.

The MLL recombinome of acute leukemias in 2017

.

Leukemia

.

2018

;

32

(

2

):

273

-

284

.

doi:10.1038/leu.2017.213

.

18.

Richard-Carpentier

G

,

Kantarjian

HM

,

Tang

G

, et al.

Outcomes of acute lymphoblastic leukemia with KMT2A (MLL) rearrangement: the MD Anderson experience

.

Blood Adv

.

2021

;

5

(

23

):

5415

-

5419

.

doi:10.1182/bloodadvances.2021004580

.

19.

Lamble

AJ

,

Myers

RM

,

Taraseviciute

A

, et al.

Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cells

.

Blood Adv

.

2023

;

7

(

4

):

575

-

585

.

doi:10.1182/bloodadvances.2022007423

.

20.

Haddox

CL

,

Mangaonkar

AA

,

Chen

D

, et al.

Blinatumomab-induced lineage switch of B-ALL with t(4:11)(q21;q23) KMT2A/AFF1 into an aggressive AML: pre- and post-switch phenotypic, cytogenetic and molecular analysis

.

Blood Cancer J

.

2017

;

7

(

9

):

e607

.

doi:10.1038/bcj.2017.89

.

21.

Jabbour

E

,

Advani

AS

,

Stelljes

M

, et al.

Prognostic implications of cytogenetics in adults with acute lymphoblastic leukemia treated with inotuzumab ozogamicin

.

Am J Hematol

.

2019

;

94

(

4

):

408

-

416

.

doi:10.13039/100004319

.

22.

Issa

GC

,

Aldoss

I

,

DiPersio

J

, et al.

The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia

.

Nature

.

2023

;

615

(

7954

):

920

-

924

.

doi:10.1038/s41586-023-05812-3

.

23.

Perner

F

,

Stein

EM

,

Wenge

DV

, et al.

MEN1 mutations mediate clinical resistance to menin inhibition

.

Nature

.

2023

;

615

(

7954

):

913

-

919

.

doi:10.1038/s41586-023-05755-9

.

24.

Richter

A

,

Lange

S

,

Holz

C

, et al.

Effective tumor cell abrogation via venetoclax-mediated BCL-2 inhibition in KMT2A-rearranged acute B-lymphoblastic leukemia

.

Cell Death Discov

.

2022

;

8

(

1

):

302

.

doi:10.1038/s41420-022-01093-3

.

25.

Patel

AA

,

Thomas

J

,

Rojek

AE

,

Stock

W.

Biology and treatment paradigms in T cell acute lymphoblastic leukemia in older adolescents and adults

.

Curr Treat Options Oncol

.

2020

;

21

(

7

):

57

.

doi:10.1007/s11864-020-00757-5

.

26.

DeAngelo

DJ

,

Yu

D

,

Johnson

JL

, et al.

Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: cancer and Leukemia Group B study 19801

.

Blood

.

2007

;

109

(

12

):

5136

-

5142

.

doi:10.1182/blood-2006-11-056754

.

27.

Dunsmore

KP

,

Winter

SS

,

Devidas

M

, et al.

Children's Oncology Group AALL0434: a phase III randomized clinical trial testing nelarabine in newly diagnosed T-cell acute lymphoblastic leukemia

.

J Clin Oncol

.

2020

;

38

(

28

):

3282

-

3293

.

doi:10.1200/JCO.20.00256

.

28.

Rowntree

CJ

,

Kirkwood

AA

,

Clifton-Hadley

L

, et al.

First analysis of the UKALL14 randomized trial to determine whether the addition of nelarabine to standard chemotherapy improves event free survival in adults with T-cell acute lymphoblastic leukaemia (CRUK/09/006)

.

Blood

.

2021

;

138

(

suppl 1

):

366

.

doi:10.1182/blood-2021-152355

.

29.

Vogiatzi

F

,

Winterberg

D

,

Lenk

L

, et al.

Daratumumab eradicates minimal residual disease in a preclinical model of pediatric T-cell acute lymphoblastic leukemia

.

Blood

.

2019

;

134

(

8

):

713

-

716

.

doi:10.1182/blood.2019000904

.

30.

Naik

J

,

Themeli

M

,

de Jong-Korlaar

R

, et al.

CD38 as a therapeutic target for adult acute myeloid leukemia and T-cell acute lymphoblastic leukemia

.

Haematologica

.

2019

;

104

(

3

):

e100

-

e103

.

doi:10.3324/haematol.2018.192757

.

31.

Saygin

C

,

Giordano

G

,

Shimamoto

K

, et al.

Dual targeting of apoptotic and signaling pathways in T-lineage acute lymphoblastic leukemia

.

Clin Cancer Res

.

2023

;

29

(

16

):

3151

-

3161

.

doi:10.1158/1078-0432.CCR-23-0415

.

32.

Pullarkat

VA

,

Lacayo

NJ

,

Jabbour

E

, et al.

Venetoclax and navitoclax in combination with chemotherapy in patients with relapsed or refractory acute lymphoblastic leukemia and lymphoblastic lymphoma

.

Cancer Discov

.

2021

;

11

(

6

):

1440

-

1453

.

doi:10.1158/2159-8290.CD-20-1465

.

33.

Laukkanen

S

,

Gronroos

T

,

Polonen

P

, et al.

In silico and preclinical drug screening identifies dasatinib as a targeted therapy for T-ALL

.

Blood Cancer J

.

2017

;

7

(

9

):

e604

.

doi:10.1038/bcj.2017.87

.

34.

Ghobadi

A

,

Aldoss

I

,

Locke

FL

, et al.

A phase 1/2 dose-escalation and dose-expansion study of the safety and efficacy of anti-CD7 allogeneic CAR-T cells (WU-CART-007) in patients with relapsed or refractory T-cell acute lymphoblastic leukemia (T-ALL)/lymphoblastic lymphoma (LBL)

.

Blood

.

2021

;

138

(

suppl 1

):

4829

.

doi:10.1182/blood-2021-146841

.

35.

Zhang

Y

,

Li

C

,

Du

M

, et al.

Allogenic and autologous anti-CD7 CAR-T cell therapies in relapsed or refractory T-cell malignancies

.

Blood Cancer J

.

2023

;

13

(

1

):

61

.

doi:10.1038/s41408-023-00822-w

.

36.

Muffly

LS

,

Hlubocky

FJ

,

Khan

N

, et al.

Psychological morbidities in adolescent and young adult blood cancer patients during curative-intent therapy and early survivorship: psychological morbidities in AYAs

.

Cancer

.

2016

;

122

(

6

):

954

-

961

.

doi:10.1002/cncr.29868

.

37.

Husson

O

,

Huijgens

PC

,

van der Graaf

WTA.

Psychosocial challenges and health-related quality of life of adolescents and young adults with hematologic malignancies

.

Blood

.

2018

;

132

(

4

):

385

-

392

.

doi:10.1182/blood-2017-11-778555

.

38.

Lang

MJ

,

David

V

,

Giese-Davis

J.

The age conundrum: a scoping review of younger age or adolescent and young adult as a risk factor for clinical distress, depression, or anxiety in cancer

.

J Adolesc Young Adult Oncol

.

2015

;

4

(

4

):

157

-

173

.

doi:10.1089/jayao.2015.0005

.

39.

Bhatia

S

,

Landier

W

,

Hageman

L

, et al.

6MP adherence in a multiracial cohort of children with acute lymphoblastic leukemia: a Children's Oncology Group study

.

Blood

.

2014

;

124

(

15

):

2345

-

2353

.

doi:10.1182/blood-2014-01-552166

.

40.

Bhatia

S

,

Landier

W

,

Shangguan

M

, et al.

Nonadherence to oral mercaptopurine and risk of relapse in Hispanic and non-Hispanic white children with acute lymphoblastic leukemia: a report from the Children's Oncology Group

.

J Clin Oncol

.

2012

;

30

(

17

):

2094

-

2101

.

doi:10.1200/JCO.2011.38.9924

.

41.

Schmiegelow

K

,

Heyman

M

,

Gustafsson

G

, et al.

The degree of myelosuppression during maintenance therapy of adolescents with B-lineage intermediate risk acute lymphoblastic leukemia predicts risk of relapse

.

Leukemia

.

2010

;

24

(

4

):

715

-

720

.

doi:10.1038/leu.2009.303

.

42.

Zeng

XL

,

Heneghan

MB

,

Badawy

SM.

Adherence to oral chemotherapy in acute lymphoblastic leukemia during maintenance therapy in children, adolescents, and young adults: a systematic review

.

Curr Oncol

.

2023

;

30

(

1

):

720

-

748

.

doi:10.3390/curroncol30010056

.

43.

Belsky

JA

,

Holmes

C

,

Stanek

J

,

Yeager

ND

,

Audino

AN.

Evaluating perspectives of a smartphone medication application in the adolescent and young adult oncology population: a qualitative study

.

J Adolesc Young Adult Oncol

.

2021

;

10

(

3

):

282

-

287

.

doi:10.1089/jayao.2020.0113

.

44.

Psihogios

AM

,

Li

Y

,

Ahmed

A

, et al.

Daily text message assessments of 6-mercaptopurine adherence and its proximal contexts in adolescents and young adults with leukemia: a pilot study

.

Pediatr Blood Cancer

.

2021

;

68

(

2

):

e28767

.

doi:10.1002/pbc.28767

.

45.

Bhatia

S

,

Hageman

L

,

Chen

Y

, et al.

Effect of a daily text messaging and directly supervised therapy intervention on oral mercaptopurine adherence in children with acute lymphoblastic leukemia: a randomized clinical trial

.

JAMA Netw Open

.

2020

;

3

(

8

):

e2014205

.

doi:10.1001/jamanetworkopen.2020.14205

.

46.

McGrady

ME

,

Ketterl

TG

,

Norris

RE

, et al.

Barriers to medication adherence among adolescents and young adults with cancer

.

Pediatr Blood Cancer

.

2023

;

70

(

3

):

e30186

.

doi:10.1002/pbc.30186

.

47.

Bleyer

A

,

Tai

E

,

Siegel

S.

Role of clinical trials in survival progress of American adolescents and young adults with cancer—and lack thereof

.

Pediatr Blood Cancer

.

2018

;

65

(

8

):

e27074

.

doi:10.1002/pbc.27074

.

48.

Hough

R

,

Sandhu

S

,

Khan

M

, et al.

Are survival and mortality rates associated with recruitment to clinical trials in teenage and young adult patients with acute lymphoblastic leukaemia? A retrospective observational analysis in England

.

BMJ Open

.

2017

;

7

(

10

):

e017052

.

doi:10.1136/bmjopen-2017-017052

.

49.

Wolfson

JA

,

Richman

JS

,

Sun

CL

, et al.

Causes of inferior outcome in adolescents and young adults with acute lymphoblastic leukemia: across oncology services and regardless of clinical trial enrollment

.

Cancer Epidemiol Biomarkers Prev

.

2018

;

27

(

10

):

1133

-

1141

.

doi:10.13039/100000002

.

50.

Siegel

SE

,

Stock

W

,

Johnson

RH

, et al.

Pediatric-inspired treatment regimens for adolescents and young adults with Philadelphia chromosome—negative acute lymphoblastic leukemia: a review

.

JAMA Oncol

.

2018

;

4

(

5

):

725

.

doi:10.1001/jamaoncol.2017.5305

.

51.

Mittal

N

,

Saha

A

,

Avutu

V

,

Monga

V

,

Freyer

DR

,

Roth

M.

Shared barriers and facilitators to enrollment of adolescents and young adults on cancer clinical trials

.

Sci Rep

.

2022

;

12

(

1

):

3875

.

doi:10.1038/s41598-022-07703-5

.

52.

Parsons

HM

,

Penn

DC

,

Li

Q

, et al.

Increased clinical trial enrollment among adolescent and young adult cancer patients between 2006 and 2012-2013 in the United States

.

Pediatr Blood Cancer

.

2019

;

66

(

1

):

e27426

.

doi:10.1002/pbc.27426

.

53.

Avutu

V

,

Monga

V

,

Mittal

N

, et al.

Use of communication technology to improve clinical trial participation in adolescents and young adults with cancer: consensus statement from the Children's Oncology Group Adolescent and Young Adult Responsible Investigator Network

.

JCO Oncol Pract

.

2022

;

18

(

3

):

224

-

231

.

doi:10.1200/op.21.00554

.

54.

Muffly

L

,

Alvarez

E

,

Lichtensztajn

D

,

Abrahão

R

,

Gomez

SL

,

Keegan

T.

Patterns of care and outcomes in adolescent and young adult acute lymphoblastic leukemia: a population-based study

.

Blood Adv

.

2018

;

2

(

8

):

895

-

903

.

doi:10.1182/bloodadvances.2017014944

.

55.

Tasian

SK

,

Hunter

DS

,

Chen

IML

, et al.

A phase 2 study of ruxolitinib with chemotherapy in children with Philadelphia chromosome-like acute lymphoblastic leukemia (AALL1521/INCB18424-269): biologic characteristics and minimal residual disease response of patients with non-CRLF2- rearranged JAK pathway alterations

.

Blood

.

2022

;

140

(

suppl 1

):

6117

-

6118

.

doi:10.1182/blood-2022-164699

.

56.

Jain

N

,

Jabbour

EJ

,

McKay

PZ

, et al.

Ruxolitinib or dasatinib in combination with chemotherapy for patients with relapsed/refractory Philadelphia (Ph)-like acute lymphoblastic leukemia: a phase I-II trial

.

Blood

.

2017

;

130

(

suppl 1

):

1322

.

doi:10.1182/blood.V130.Suppl_1.1322.1322

.

57.

Ravandi

F

,

Kishtagari

A

,

Carraway

HE

, et al.

COVALENT-101: phase 1 study of BMF-219, a novel oral irreversible menin inhibitor, in patients with relapsed/refractory (R/R) acute leukemia (AL), diffuse large B-cell lymphoma (DLBCL), and multiple myeloma (MM)

.

J Clin Oncol

.

2022

;

40

(

suppl 16

):

TPS7064

-

TPS7064

.

doi:10.1200/JCO.2022.40.16_suppl.TPS7064

.

58.

Daver

NG

,

Affinito

J

,

Cai

H

, et al.

Phase 1/2, open-label, dose-escalation, dose-expansion study of menin inhibitor DSP-5336 in adult patients with acute leukemia with and without mixed-lineage leukemia (MLL)- rearrangement (r) or nucleophosmin 1 (NPM1) mutation (m)

.

J Clin Oncol

.

2022

;

40

(

suppl 16

):

TPS7066

-

TPS7066

.

doi:10.1182/blood-2022-167674

.

59.

Goekbuget

N

,

Fiedler

W

,

Alakel

N

, et al.

Results of the risk-adapted, MRD-stratified GMALL trial 08/2013 in 281 T-ALL/T-Lbl patients: excellent outcome of standard risk thymic T-ALL

.

Blood

.

2022

;

140

(

suppl 1

):

115

-

117

.

doi:10.1182/blood-2022-158381

.

60.

Guru Murthy

GS

,

Kearl

TJ

,

Cui

W

, et al.

A phase 1 study of XmAb18968, a CD3-CD38 bispecific antibody for the treatment of patients with relapsed/refractory acute leukemia and T cell lymphoblastic lymphoma

.

Blood

.

2021

;

138

(

suppl 1

):

4401

.

doi:10.1182/blood-2021-149329

.